Evista: Advanced Osteoporosis Prevention and Treatment
Evista
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.67 | $50.00 (0%) | 🛒 Add to cart |
| 60 | $1.30 | $100.00 $78.00 (22%) | 🛒 Add to cart |
| 90 | $1.18 | $150.00 $106.00 (29%) | 🛒 Add to cart |
| 120 | $1.12 | $200.00 $135.00 (32%) | 🛒 Add to cart |
| 180 | $1.06 | $300.00 $191.00 (36%) | 🛒 Add to cart |
| 270 | $1.02 | $450.00 $276.00 (39%) | 🛒 Add to cart |
| 360 | $1.00
Best per pill | $600.00 $361.00 (40%) | 🛒 Add to cart |
Synonyms | |||
Evista (raloxifene hydrochloride) is a selective estrogen receptor modulator (SERM) specifically engineered for the management and prevention of osteoporosis in postmenopausal women. It offers a targeted therapeutic approach that combines the beneficial effects of estrogen on bone density with a favorable safety profile regarding certain tissues. This medication represents a significant advancement in long-term skeletal health management, providing a non-hormonal alternative for patients who require effective bone protection without the risks associated with conventional hormone replacement therapy. Clinicians value Evista for its dual-action capacity in reducing vertebral fracture risk while modulating estrogenic activity in a tissue-selective manner.
Features
- Contains 60 mg raloxifene hydrochloride per tablet
- Selective estrogen receptor modulator (SERM) class medication
- Oral administration once daily
- Demonstrated efficacy in clinical trials lasting up to 8 years
- Available in blister packs of 28 tablets
- Temperature-stable formulation
- White, elliptical, film-coated tablets
Benefits
- Significantly reduces risk of vertebral fractures by approximately 30-50% in postmenopausal women with osteoporosis
- Increases bone mineral density (BMD) at both lumbar spine and hip regions
- Provides estrogen-like protective effects on bone without stimulating uterine tissue
- Lowers risk of invasive breast cancer in postmenopausal women with osteoporosis
- Non-hormonal mechanism of action avoids many traditional hormone therapy concerns
- Convenient once-daily dosing supports long-term adherence to therapy
Common use
Evista is primarily indicated for the treatment and prevention of osteoporosis in postmenopausal women. It is particularly valuable for patients who cannot or prefer not to use estrogen therapy but require effective bone protection. The medication is also approved for risk reduction of invasive breast cancer in postmenopausal women with osteoporosis or those at high risk for invasive breast cancer. Clinical use typically involves patients who have undergone natural or surgical menopause and demonstrate low bone mineral density or other risk factors for osteoporotic fractures. Treatment is generally long-term, as bone protective effects develop progressively over months of continuous therapy.
Dosage and direction
The recommended dosage is one 60 mg tablet taken orally once daily, with or without food. Patients should swallow the tablet whole with water; it should not be crushed, chewed, or broken. Administration may occur at any time of day, though consistency in timing is recommended to maintain stable drug levels and support adherence. If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Treatment duration should be individualized based on therapeutic response, fracture risk assessment, and ongoing evaluation of benefit-risk ratio. Regular monitoring of bone mineral density is recommended, typically at 1-2 year intervals during treatment.
Precautions
Patients should undergo thorough clinical assessment before initiating therapy, including evaluation of personal and family history of venous thromboembolism. Regular gynecological examinations are recommended as endometrial changes may occur despite the drug’s neutral effect on uterine tissue in most patients. Hepatic function should be monitored periodically, as raloxifene is extensively metabolized in the liver. Patients should be advised to discontinue therapy at least 72 hours prior to prolonged immobilization and during periods of extended bed rest. Caution is warranted in women with a history of stroke or other cerebrovascular events, as increased risk of fatal stroke has been observed in clinical trials. Supplemental calcium and vitamin D intake should be maintained unless contraindicated.
Contraindications
Evista is contraindicated in women with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. It must not be used during pregnancy or in women who may become pregnant, as it may cause fetal harm. The medication is contraindicated in nursing mothers and in patients with known hypersensitivity to raloxifene hydrochloride or any component of the formulation. Women with hepatic impairment or cholestasis should avoid use due to altered metabolism and excretion. Concurrent use with estrogen-containing therapies is not recommended. The drug is contraindicated in premenopausal women and should not be used in patients with unexplained uterine bleeding.
Possible side effects
The most serious adverse reactions include venous thromboembolism (deep vein thrombosis, pulmonary embolism) and increased risk of fatal stroke. Common side effects (occurring in >5% of patients) comprise hot flashes, leg cramps, peripheral edema, flu-like syndrome, arthralgia, and sweating. Less frequent reactions include insomnia, rash, nausea, vomiting, and weight gain. Venous thromboembolic events typically occur during the first four months of treatment. Hot flashes are most prevalent during the initial six months of therapy and generally diminish with continued treatment. Patients may experience triglyceride elevation, though clinical significance remains uncertain. Rare cases of thrombocytopenia and gastrointestinal disturbances have been reported.
Drug interaction
Raloxifene undergoes extensive hepatic glucuronidation and may interact with drugs that affect this metabolic pathway. Cholestyramine and other anion-exchange resins significantly reduce absorption and should not be administered concurrently. Warfarin and other highly protein-bound drugs may require dosage adjustment due to potential displacement from protein binding sites. Concurrent use with systemic estrogens is not recommended. Ampicillin and other antibiotics that reduce enteric bacteria may decrease enterohepatic cycling of raloxifene. The medication may reduce the effectiveness of thyroid hormone replacement therapy. Clinicians should exercise caution when co-administering with other extensively protein-bound drugs such as diazepam, diazoxide, and non-steroidal anti-inflammatory drugs.
Missed dose
If a dose is forgotten, the patient should take it as soon as remembered on the same day. If the missed dose is not remembered until the next day, the patient should skip the missed dose and resume the regular dosing schedule. Doubling the dose to make up for a missed dose is not recommended. Consistent daily administration is important for maintaining therapeutic effect, particularly given the drug’s mechanism of action on bone remodeling. Patients should be educated about the importance of adherence and provided with strategies to support regular dosing, such as pill organizers or daily reminders. If multiple doses are missed, consultation with a healthcare provider is advised to assess是否需要 additional monitoring.
Overdose
Limited information exists regarding human overdose experience. In clinical trials, single doses of up to 600 mg have been administered without serious adverse effects. Expected manifestations may include exacerbation of known side effects, particularly leg cramps, flushing, and gastrointestinal discomfort. There is no specific antidote for raloxifene overdose. Management should consist of symptomatic and supportive care, including monitoring for signs of venous thromboembolism. Gastric lavage may be considered if ingestion occurred within a short time frame. Activated charcoal administration could be beneficial if given promptly after ingestion. Due to extensive protein binding, dialysis is unlikely to be effective. Patients should seek immediate medical attention if overdose is suspected.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep the tablets in their original blister packaging until immediately before use to protect from moisture and light. The medication should be stored in a dry place and kept out of reach of children and pets. Do not transfer tablets to other containers, as this may compromise stability. Discard any medication that has expired or shows signs of deterioration, such as discoloration or physical damage. Proper disposal methods should follow local regulations for pharmaceutical waste, typically through drug take-back programs or community disposal systems.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Healthcare professionals should exercise their own clinical judgment when prescribing Evista, considering individual patient factors and current clinical guidelines. Patients must consult with qualified healthcare providers for personalized medical advice and treatment decisions. The manufacturer and distributors are not liable for any consequences arising from the use or misuse of this information. Full prescribing information including boxed warnings should be reviewed before initiating therapy. Treatment decisions should be based on comprehensive assessment of benefits versus risks for each individual patient.
Reviews
Clinical studies demonstrate that Evista significantly reduces vertebral fracture risk by 30-50% in postmenopausal women with osteoporosis over 3 years of treatment. The MORE trial (Multiple Outcomes of Raloxifene Evaluation) involving 7,705 postmenopausal women showed 68% reduction in new vertebral fractures among women with pre-existing fractures. Patient-reported outcomes indicate generally good tolerability, though vasomotor symptoms may affect quality of life initially. Long-term extension studies (up to 8 years) confirm maintained efficacy in fracture risk reduction with persistent BMD improvements. Healthcare providers appreciate the dual benefit of fracture prevention and breast cancer risk reduction, though careful patient selection remains crucial given the thromboembolic risk profile. Real-world evidence supports the clinical trial findings regarding effectiveness and safety when used in appropriate patient populations.